Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,448 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rested Clear all
Completed Phase 3 Interventional

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

NCT02455245
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Carboplatin and Vincristine, Carboplatin
Drug
Lead sponsor
Alicia Lenzen
Other
Eligibility
Up to 21 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
21
States / cities
Phoeniz, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

NCT01520805
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 21, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

NCT03670030
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
ABI-009
Drug
Lead sponsor
Robert Ramirez
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

NCT01279603
View directory record Official record
Conditions
Solid Tumors
Interventions
GO-203-2c
Drug
Lead sponsor
Genus Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 21, 2026, 8:13 PM EDT
Not listed Not applicable Interventional

Impact of Acute Exercise on Vascular Insulin Sensitivity in Metabolic Syndrome

NCT03894527
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Single Bout of Exercise, Control Condition
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients

NCT02184494
View directory record Official record
Conditions
Parkinson's Disease, Multiple Sclerosis
Interventions
pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Device
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 8:13 PM EDT
Terminated Phase 3 Interventional

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

NCT00358566
View directory record Official record
Conditions
Advanced Unresectable Pancreatic Cancer
Interventions
GV1001, Gemcitabine (Chemotherapy)
Biological · Drug
Lead sponsor
Pharmexa A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Mobile, Alabama • Hot Springs, Arkansas • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 21, 2026, 8:13 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional

Identify the Optimal TMS Target to Modulate Reward Activity

NCT05766254
View directory record Official record
Conditions
Nicotine Use Disorder
Interventions
Active 10-Hz TMS to the DLPFC, Sham TMS-DLPFC
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 21, 2026, 8:13 PM EDT
Withdrawn Phase 4 Interventional

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

NCT00625469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional

Functional Outcomes in CondUction System Pacing and Right Ventricular Synchrony (FOCUS-Right)

NCT06601322
View directory record Official record
Conditions
Left Branch Bundle Block, RV - Right Ventricular Abnormality
Interventions
Pacemaker Interrogation and Electrocardiogram (ECG):, Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR, Continuous pacemaker telemetry (CPT)
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Effectiveness Trial for Evaluating IAHA for PFPS

NCT01811654
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Intra-Articular Hyaluronic Acid-Euflexxa
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 21, 2026, 8:13 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions

NCT01306994
View directory record Official record
Conditions
Arthrogryposis, Craniofacial Abnormalities
Interventions
Lactate, Glucose, and Adenosine Triphosphate Blood Levels, Physiological Stress Test, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, Observational Gait Analysis, Mental Health Interview
Other · Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormones and Social Anxiety Disorder Treatment

NCT02482805
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01134341
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Monitor Validation

NCT03617705
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA App, Skyn Monitor Lab Session 2
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

NCT02770313
View directory record Official record
Conditions
Intermittent Fasting
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 21, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01068782
View directory record Official record
Conditions
Astrocytic Tumors
Interventions
Cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Encinitas, California • Pleasant Hill, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Bipolar Transcranial Alternating Current Stimulation (tACS)

NCT05480124
View directory record Official record
Conditions
Bipolar Disorder
Interventions
tACS brain stimulation treatment, Sham stimulation treatment
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 21, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 21, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional

MENTOR Wellness Program

NCT06148324
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
MENTOR Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Enrolling by invitation Not applicable Interventional

Effects of Accelerated rTMS on Sleep Architecture in Chronic Insomnia Disorder

NCT07595185
View directory record Official record
Conditions
Insomnia, Chronic Insomnia, Chronic Insomnia Disorder, Sleep Disturbance
Interventions
TMS
Device
Lead sponsor
San Francisco Neurology and Sleep Center
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Results available

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

NCT00562640
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 21, 2026, 8:13 PM EDT